Troubled Dendreon pursues new biomarkers for Provenge; Exagen lands $25M loan for rheumatology tests;

> Despite falling sales and a so-far failed effort to find a buyer, Dendreon ($DNDN) continues to pursue new research into biomarkers that could be used to guide the use of Provenge. Story

> Exagen Diagnostics has nailed down a loan for up to $25 million that will help the company expand sales efforts for its rheumatology tests. Report

> A new report from Decision Resources concludes that while biomarkers have been most useful in oncology, they are also playing a growing role for chronic conditions. Release

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.